Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 7/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 6/20 | 0.36 |
| ▸ | CDC7 | O00311 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL962978 | 1.00 | MTNR1A (0.40) | MTNR1APARP1SLC22A12TBXAS1CDC7 | |
| SCHEMBL963804 | 0.86 | MTNR1A (0.38) | MTNR1APARP1SLC22A12CDC7CDK2 | |
| SCHEMBL963808 | 0.85 | PPARG (0.39) | MTNR1APARP1SLC22A12CDC7CDK2 | |
| SCHEMBL962499 | 0.82 | CDC7 (0.41) | MTNR1APARP1SLC22A12CDC7CDK2 | |
| SCHEMBL967688 | 0.79 | PARP1 (0.40) | MTNR1APARP1SLC22A12TBXAS1CDC7 | |
| SCHEMBL967690 | 0.79 | PARP1 (0.40) | MTNR1APARP1SLC22A12TBXAS1CDC7 | |
| SCHEMBL966695 | 0.79 | PPARG (0.37) | MTNR1AENPP1ENPP3 | |
| SCHEMBL966698 | 0.79 | PPARG (0.37) | MTNR1AENPP1ENPP3 | |
| SCHEMBL963810 | 0.76 | MTNR1A (0.41) | MTNR1APARP1SLC22A12CDC7CDK2 | |
| SCHEMBL963806 | 0.76 | MTNR1A (0.41) | MTNR1APARP1SLC22A12CDC7CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | MTNR1A 310/4885PARP1 1867/4885SLC22A12 538/4885 |
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | MTNR1A 69/4885PARP1 1594/4885SLC22A12 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.